Parkinson Disease
Conditions
Brief summary
The primary objective of this study was to describe neurologists' population of patients treated with pramipexole and suffering from Parkinson's disease (so called 'primary care' population). The secondary objectives were: * Evaluate the mean dose of pramipexole prescribed under actual conditions of use depending on the severity of the disease. * Evaluate the reasons for choosing pramipexole as treatment. * Identify the patient profiles determining the choice of dose of pramipexole prescribed
Interventions
DRUGPramipexole
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients suffering from idiopathic Parkinson's Disease and treated with pramipexole for at least two months, examined in consultation
Exclusion criteria
* Patient refusing to take part * Patient taking part in a clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of Patient's demographic characteristics | 9 months |
| Assessment of Parkinson's disease characteristics | 9 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Description of the actual treatments of PD | 9 months | — |
| Evaluation for reasons for choosing pramipexole as treatment | 9 months | — |
| Assessment of Severity of the Parkinson Disease (PD) | 9 months | (levels of severity of the disease were defined with the scientific committee in 5 stages: treatment initiation phase, honeymoon phase, therapeutic insufficiency phase, start of motor complications phase and advanced motor complications phase) |
| Evaluation of the state of health perceived by the patient using the questionnaire EQ-5D | 9 months | — |
| Number of patients with adverse events | 9 months | — |
| Assessment of Treatment history | 9 months | 3 subgroups: Initiation: no antiparkinson treatment before the implementation of pramipexole Switch: at least one dopamine agonist replaced by pramipexole Add on: pramipexole is implemented in addition to the previous treatment |
| Assessment of Disease Stage Stage according to Hoehn and Yahr and Unified Parkinson Disease Rating Scale III (UPDRS III) scores | 9 months | — |
Outcome results
None listed